Relapsing-Remitting|OMICS International|Journal Of Neurology And Neurophysiology

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.


Quality of life assessment in patients with multiple sclerosis has gained increasing importance as it encompasses all aspects of patients’ lives that may be affected by the disease. Though patients’ quality of life worsens as multiple sclerosis progresses and physical function deteriorates, it depends not only on the disability caused by physical limitations but also on their emotional status, which may also affect the perception of wellbeing and quality of life scenario, depression has been shown to have a notable impact on quality of life, and is considered a significant and independent predictor of impaired quality of life. Sexual dysfunction is another common and often underestimated clinical symptom of multiple sclerosis that, along with its emotional repercussions, has been shown to affect patients’ quality of life. First-line disease-modifying drugs for relapsing-remitting multiple sclerosis including interferon-beta (INFb)-1a, INFb-1b and glatiramer acetate have been shown to improve the course of the disease. However, their effect on patients’ quality of life has not yet been fully clarified. Indeed, the information available on INFb's effect on quality of life is controversial, ranging from some benefit to absence of effect or even to quality of life detriment.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on April, 2021